IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Related Keywords

Pennsylvania , United States , Fox Chase , University Of Pennsylvania , New York , Philadelphia , Edmundm Dunn , Hossein Borghaei , Merck Celgene , Amgen , Pfizer , Novartis , Genentech , Department Of Hematology Oncology , Cart Program , Thoracic Oncology At Fox Chase Cancer Center , Division Of Thoracic Medical Oncology , Safety Monitoring Board For University Of Pennsylvania , Astrazeneca , Boehringer Ingelheim , Annual New York Lung Cancers Symposium , Thoracic Medical Oncology , Immune Monitoring Facility , Thoracic Oncology , Fox Chase Cancer Center , World Data , Advisory Board , Scientific Advisory Board , Stock Options , Safety Monitoring Board ,